Appendix 4E

Key points

• Income from ordinary activities increased by 51.6% to $39,677,397
• Loss from ordinary activities after tax decreased by 13.8% to $(43,341,565)
• No dividends paid, recommended, or declared during the period

Full summary

PYC Therapeutics Ltd, a clinical-stage biotechnology company, reported its preliminary financial results for the year ended 30 June 2026. The company saw a 51.6% increase in income from ordinary activities to $39,677,397, while losses from ordinary activities after tax decreased by 13.8% to $(43,341,565). Net tangible assets per ordinary security increased from 28.56 cents to 70.13 cents. The company maintained its equity share in Vision Pharma Limited at 97.1%. No dividends were paid, recommended, or declared during the financial year.